WO2017059380A1 - Binding molecules with modified j-chain - Google Patents

Binding molecules with modified j-chain Download PDF

Info

Publication number
WO2017059380A1
WO2017059380A1 PCT/US2016/055041 US2016055041W WO2017059380A1 WO 2017059380 A1 WO2017059380 A1 WO 2017059380A1 US 2016055041 W US2016055041 W US 2016055041W WO 2017059380 A1 WO2017059380 A1 WO 2017059380A1
Authority
WO
WIPO (PCT)
Prior art keywords
igg
igm
iga
binding
adme
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2016/055041
Other languages
English (en)
French (fr)
Inventor
Bruce Keyt
Leonard George Presta
Ramesh Baliga
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
IGM Biosciences Inc
Original Assignee
IGM Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FIEP16784320.0T priority Critical patent/FI3355913T3/fi
Priority to CN201680069842.XA priority patent/CN108463245A/zh
Priority to EP20204954.0A priority patent/EP3824903A1/en
Priority to JP2018516668A priority patent/JP7065766B2/ja
Priority to EP16784320.0A priority patent/EP3355913B1/en
Priority to SI201631864T priority patent/SI3355913T1/sl
Priority to CA2999284A priority patent/CA2999284C/en
Priority to ES16784320T priority patent/ES2996834T3/es
Priority to DK16784320.0T priority patent/DK3355913T3/da
Priority to PL16784320.0T priority patent/PL3355913T3/pl
Priority to US15/764,859 priority patent/US10618978B2/en
Priority to AU2016329197A priority patent/AU2016329197B2/en
Application filed by IGM Biosciences Inc filed Critical IGM Biosciences Inc
Publication of WO2017059380A1 publication Critical patent/WO2017059380A1/en
Anticipated expiration legal-status Critical
Priority to US16/745,059 priority patent/US11542342B2/en
Priority to AU2021200348A priority patent/AU2021200348B2/en
Priority to JP2022072055A priority patent/JP7314356B2/ja
Priority to US18/054,776 priority patent/US12486336B2/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2881—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD71
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/735—Fusion polypeptide containing domain for protein-protein interaction containing a domain for self-assembly, e.g. a viral coat protein (includes phage display)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/90—Fusion polypeptide containing a motif for post-translational modification
    • C07K2319/91—Fusion polypeptide containing a motif for post-translational modification containing a motif for glycosylation

Definitions

  • Immune checkpoints refer to inhibitory signaling pathways that are encoded into the immune system, and which play a vital role in maintaining self- tolerance, as well as modulating the duration and amplitude of immune responses. See, e.g., Pardoll, Drew M. "The blockade of immune checkpoints in cancer immunotherapy.” Nature Reviews Cancer 12.4 (2012): 252-264; Postow, Michael A. et al., "Immune Checkpoint Blockade in Cancer Therapy," J Clin Oncol. 2015 Jun 10;33(17): 1974-82. doi: 10.1200/JCO.2014.59.4358.
  • the invention is further based on the recognition that due to their multivalent nature, IgM, IgA, IgG/IgM or IgG/IgA antibodies can provide increased avidity between the antibody and a target antigen, thereby facilitating binding of antigens with low level expression and/or low binding affinity. Furthermore, the optional multi-specific nature of the IgM, IgA, IgG/IgM or IgG/IgA portion of the subject binding molecules allows binding between specific numbers and/or specific types of binding targets, thereby facilitating binding between specific combinations of antigen targets.
  • the modified J-chain portion of the subject binding molecules comprises an ADME-modulating moiety, which facilitates an increased concentration and/or an increased half-life in a target tissue.
  • the modified J-chain is in a J-linker-ADME orientation, with the ADME- modulating moiety at a C-terminus of the modified J-chain.
  • the modified J-chain further comprises a second binding moiety. In some embodiments, the
  • FIG. 6 shows SDS PAGE analysis of anti-CD20 IgM antibodies with or without various anti-CD3 binding moieties on the J-chain in either orientation. J-chain containing IgM pentamers are easily distinguished from the hexameric IgM without J-chain.
  • FIG. 23 is an image of a reducing PAGE gel and a Western blot analysis of the antibodies listed in the table, one of which (1.5.3V15J15ABD) has bidentate J-chain configuration.
  • FIG. 26, Panel A is a graph showing concentration as a function of time for an IgM antibody that has a V-J-ABD bidentate J-chain configuration.
  • Panel B is a graph showing concentration as a function of time for an IgM antibody that has a V-J-HSA bidentate J-chain configuration.
  • Humanized forms of non-human (e.g., murine) antibodies are antibodies which contain minimal sequence derived from non-human immunoglobulin.
  • humanized antibodies are human immunoglobulins (recipient antibody) in which residues from a hypervariable region of the recipient are replaced by residues from a hypervariable region of a non-human species (donor antibody) such as mouse, rat, rabbit or nonhuman primate having the desired specificity, affinity, and capacity.
  • donor antibody such as mouse, rat, rabbit or nonhuman primate having the desired specificity, affinity, and capacity.
  • Fv framework region (FR) residues of the human immunoglobulin are also replaced by corresponding non- human residues.
  • humanized antibodies may comprise residues which are not found in the recipient antibody or in the donor antibody. These modifications are made to further refine antibody performance.
  • epitope includes any molecular determinant capable of specific binding to an antibody.
  • epitope determinants include chemically active surface groupings of molecules such as amino acids, sugar side chains, phosphoryl, or sulfonyl, and, in certain embodiments, may have specific three dimensional structural characteristics, and or specific charge characteristics.
  • An epitope is a region of an antigen that is bound by an antibody.
  • a "binding region” is a region on a binding target bound by a binding molecule.
  • Both IgA and IgM possess an 18-amino acid extension in the C terminus called the "tail-piece" (tp).
  • the IgM ( ⁇ ) and IgA (atp) tail-pieces differ at seven amino acid positions.
  • the IgM and IgA tail-piece is highly conserved among various animal species. The conserved penultimate cysteine residue in the IgA and IgM tail-pieces has been demonstrated to be involved in polymerization.
  • Both tail-pieces contain an N-linked carbohydrate addition site, the presence of which is required for dimer formation in IgA and J-chain incorporation and pentamer formation in IgM.
  • the structure and composition of the N-linked carbohydrates in the tail-pieces differ, suggesting differences in the accessibility of the glycans to processing by glycosyltransferases.
  • theuseofalbumin humanserum albumin
  • albumin-likeproteins e.g., albuminbindingpeptides
  • albuminbinding antibody moieties e.g., albumin binding scFv antibody fragments
  • ADME-modulating moietiesinasubjectbindingmolecule provides aneffectivestrategyformanipulatingthe pharmacokineticsofabinding molecule.
  • the neonatalFcreceptor(FcRn) is knowntoprovidearecyclingpathwaythatprovidesimmunoglobulinmoleculeswithalonger circulating half-life. E.g., Roopenian D.C. etal., NatureReviewsImmunology7, 715-725 (2007).
  • T-cell inhibitory signaling pathways are known in the art, and include, without limitation, those described in Pardoll et al. Non-limiting examples of T-cell inhibitory signaling pathways and components thereof are described in further detail below.
  • T-cell inhibitory signaling pathway is the signaling pathway involving programmed cell death- 1 (PD-1) and its ligand, programmed cell death ligand-1 (PD-L1).
  • PD-1 is an inhibitory cell surface receptor protein of the immunoglobulin superfamily, and is involved in the regulation of T-cell function in immunity and self- tolerance.
  • PD-L1 interacts with PD-1 on the surface of T-cells, and inhibits proliferation of T- cells by blocking cell cycle progression and cytokine production. Id.
  • T-cell stimulatory signaling pathways are known in the art, and include, without limitation, those described in Pardoll et al. Non-limiting examples of T-cell stimulatory signaling pathways and components thereof are described in further detail below.
  • the J-chain of a subject binding molecule includes an ADME- modulating moiety that reduces clearance of the binding molecule from the circulation of a subject, while the antibody antagonizes a T-cell inhibitory signaling pathway.
  • the purpose of such a binding molecule is to increase the half-life of the binding molecule via the J-chain ADME-modulating moiety, while simultaneously blocking or decreasing T-cell inhibitory signaling via the antibody. Due to their increased avidity, the subject IgM, IgA, IgG/IgM and IgG/IgA antibodies act as effective antagonists when directed to certain binding targets, such as members of a T-cell inhibitory signaling pathway, as described above.
  • the J-chain of the subject binding molecules includes an ADME-modulating moiety that reduces clearance of the binding molecule from the circulation of a subject, while the antibody agonizes a T-cell stimulatory signaling pathway.
  • the purpose of such a binding molecule is to increase the half-life of the binding molecule via the ADME-modulating moiety on the J-chain, while simultaneously maintaining or increasing T-cell stimulatory signaling via the antibody. Due to their increased avidity, the subject IgM, IgA, IgG/IgM and IgG/IgA antibodies act as super agonists when directed to certain binding targets, such as members of a T-cell stimulatory signaling pathway, as described above.
  • the J-chain of a subject binding molecule includes an ADME- modulating moiety that increases the retention of the binding molecule in an extra-vascular space, while the antibody binds to a binding target in the extra-vascular space.
  • the purpose of such a binding molecule is to increase the residence time of the binding molecule in the extra-vascular space via the ADME-modulating moiety on the J- chain, while simultaneously binding to a binding target using the higher avidity of the subject IgM, IgA, IgG/IgM and IgG/IgA antibodies.
  • Such binding molecules find utility in the treatment of diseases or disorders wherein high avidity binding to a binding target in an extra- vascular space is beneficial.
  • a binding molecule whose IgM, IgA, IgG/IgM, or IgG/IgA antibody binds to PD-1 and antagonizes a PD-l-mediated T-cell inhibitory signaling pathway has an ADME-modulating moiety on the J-chain that comprises a transferrin receptor-binding scFv antibody fragment.
  • a binding molecule whose IgM, IgA, IgG/IgM, or IgG/IgA antibody binds to PD-Ll and antagonizes a PD-Ll -mediated T-cell inhibitory signaling pathway has an ADME-modulating moiety on the J-chain that comprises insulin.
  • a binding molecule whose IgM, IgA, IgG/IgM, or IgG/IgA antibody binds to PD-Ll and antagonizes a PD-Ll -mediated T-cell inhibitory signaling pathway has an ADME-modulating moiety on the J-chain that comprises an insulin receptor-binding antibody moiety.
  • a binding molecule whose IgM, IgA, IgG/IgM, or IgG/IgA antibody binds to PD-Ll and antagonizes a PD-Ll - mediated T-cell inhibitory signaling pathway has an ADME-modulating moiety on the J-chain that comprises an insulin receptor-binding scFv antibody fragment.
  • a binding molecule whose IgM, IgA, IgG/IgM, or IgG/IgA antibody binds to PD-L1 and antagonizes a PD-L1 -mediated T-cell inhibitory signaling pathway has an ADME-modulating moiety on the J-chain that comprises a Glutl-binding scFv antibody fragment.
  • a binding molecule whose IgM, IgA, IgG/IgM, or IgG/IgA antibody binds to TIM3 and antagonizes a TIM3 -mediated T-cell inhibitory signaling pathway has an ADME-modulating moiety on the J-chain that comprises human serum albumin.
  • a binding molecule whose IgM, IgA, IgG/IgM, or IgG/IgA antibody binds to TIM3 and antagonizes a TIM3-mediated T-cell inhibitory signaling pathway has an ADME-modulating moiety on the J-chain that comprises a human serum albumin-binding peptide.
  • a binding molecule whose IgM, IgA, IgG/IgM, or IgG/IgA antibody binds to LAG3 and antagonizes a LAG3 -mediated T-cell inhibitory signaling pathway has an ADME-modulating moiety on the J-chain that comprises an Fc domain.
  • a binding molecule whose IgM, IgA, IgG/IgM, or IgG/IgA antibody binds to CD137 and agonizes a CD137-mediated T-cell inhibitory signaling pathway has an ADME-modulating moiety on the J-chain that comprises an Fc domain.
  • a binding molecule whose IgM, IgA, IgG/IgM, or IgG/IgA antibody binds to OX40 and agonizes an OX40-mediated T-cell inhibitory signaling pathway has an ADME-modulating moiety on the J-chain that comprises a leptin receptor-binding scFv antibody fragment.
  • IgG/IgA antibody binds to CD40 and agonizes a CD40-mediated T-cell inhibitory signaling pathway has an ADME-modulating moiety on the J-chain that comprises basigin.
  • a binding molecule whose IgM, IgA, IgG/IgM, or IgG/IgA antibody binds to CD40 and agonizes a CD40-mediated T-cell inhibitory signaling pathway has an ADME-modulating moiety on the J-chain that comprises a basigin-binding antibody moiety.
  • a binding molecule whose IgM, IgA, IgG/IgM, or IgG/IgA antibody binds to GITR and agonizes a GITR-mediated T-cell inhibitory signaling pathway has an ADME-modulating moiety on the J-chain that comprises IGF-1.
  • a binding molecule whose IgM, IgA, IgG/IgM, or IgG/IgA antibody binds to GITR and agonizes a GITR-mediated T-cell inhibitory signaling pathway has an ADME-modulating moiety on the J-chain that comprises an IGF-1 -binding antibody moiety.
  • a binding molecule whose IgM, IgA, IgG/IgM, or IgG/IgA antibody binds to CD27 and agonizes a CD27-mediated T-cell inhibitory signaling pathway has an ADME-modulating moiety on the J-chain that comprises a basigin-binding scFv antibody fragment.
  • a binding molecule whose IgM, IgA, IgG/IgM, or IgG/IgA antibody binds to amyloid beta has an ADME-modulating moiety on the J-chain that comprises human serum albumin.
  • a binding molecule whose IgM, IgA, IgG/IgM, or IgG/IgA antibody binds to amyloid beta has an ADME-modulating moiety on the J-chain that comprises a human serum albumin-binding peptide.
  • a binding molecule whose IgM, IgA, IgG/IgM, or IgG/IgA antibody binds to BACE has an ADME-modulating moiety on the J-chain that comprises a CD98hc-binding scFv antibody fragment.
  • IgM heavy chain This heavy chain construct has a full length ⁇ chain for an anti- CD20 IgM which binds CD20 on the surface of B-cells:
  • Example 5 Use of site specific chemoenzymatic labeling to generate imaging agents and antibody drug conjugates with IgMs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
PCT/US2016/055041 2015-09-30 2016-09-30 Binding molecules with modified j-chain Ceased WO2017059380A1 (en)

Priority Applications (16)

Application Number Priority Date Filing Date Title
CN201680069842.XA CN108463245A (zh) 2015-09-30 2016-09-30 具有修饰的j链的结合分子
EP20204954.0A EP3824903A1 (en) 2015-09-30 2016-09-30 Binding molecules with modified j-chain
JP2018516668A JP7065766B2 (ja) 2015-09-30 2016-09-30 改変ｊ鎖を有する結合分子
EP16784320.0A EP3355913B1 (en) 2015-09-30 2016-09-30 Binding molecules with modified j-chain
SI201631864T SI3355913T1 (sl) 2015-09-30 2016-09-30 Vezalne molekule z modificirano j-verigo
CA2999284A CA2999284C (en) 2015-09-30 2016-09-30 Binding molecules with modified j-chain
ES16784320T ES2996834T3 (en) 2015-09-30 2016-09-30 Binding molecules with modified j-chain
PL16784320.0T PL3355913T3 (pl) 2015-09-30 2016-09-30 Cząsteczki wiążące ze zmodyfikowanym łańcuchem j
DK16784320.0T DK3355913T3 (da) 2015-09-30 2016-09-30 Bindingsmolekyler med modificeret j-kæde
FIEP16784320.0T FI3355913T3 (fi) 2015-09-30 2016-09-30 Muokatun j-ketjun sisältäviä sitoutuvia molekyylejä
AU2016329197A AU2016329197B2 (en) 2015-09-30 2016-09-30 Binding molecules with modified J-chain
US15/764,859 US10618978B2 (en) 2015-09-30 2016-09-30 Binding molecules with modified J-chain
US16/745,059 US11542342B2 (en) 2015-09-30 2020-01-16 Binding molecules with modified J-chain
AU2021200348A AU2021200348B2 (en) 2015-09-30 2021-01-20 Binding molecules with modified J-chain
JP2022072055A JP7314356B2 (ja) 2015-09-30 2022-04-26 改変ｊ鎖を有する結合分子
US18/054,776 US12486336B2 (en) 2015-09-30 2022-11-11 Binding molecules with modified J-chain

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562235518P 2015-09-30 2015-09-30
US62/235,518 2015-09-30

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US15/764,859 A-371-Of-International US10618978B2 (en) 2015-09-30 2016-09-30 Binding molecules with modified J-chain
US16/745,059 Continuation US11542342B2 (en) 2015-09-30 2020-01-16 Binding molecules with modified J-chain

Publications (1)

Publication Number Publication Date
WO2017059380A1 true WO2017059380A1 (en) 2017-04-06

Family

ID=57153542

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2016/055041 Ceased WO2017059380A1 (en) 2015-09-30 2016-09-30 Binding molecules with modified j-chain

Country Status (15)

Country Link
US (3) US10618978B2 (enExample)
EP (2) EP3355913B1 (enExample)
JP (2) JP7065766B2 (enExample)
CN (1) CN108463245A (enExample)
AU (2) AU2016329197B2 (enExample)
CA (1) CA2999284C (enExample)
DK (1) DK3355913T3 (enExample)
ES (1) ES2996834T3 (enExample)
FI (1) FI3355913T3 (enExample)
HK (1) HK1252791A1 (enExample)
HU (1) HUE069387T2 (enExample)
PL (1) PL3355913T3 (enExample)
PT (1) PT3355913T (enExample)
SI (1) SI3355913T1 (enExample)
WO (1) WO2017059380A1 (enExample)

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017196867A1 (en) * 2016-05-09 2017-11-16 Igm Biosciences, Inc. Anti-pd-l1 antibodies
US9938347B2 (en) 2015-01-20 2018-04-10 Igm Biosciences A/S Tumor necrosis factor (TNF) superfamily receptor IgM antibodies and uses thereof
US10351631B2 (en) 2013-09-05 2019-07-16 Igm Biosciences, Inc. Constant chain modified bispecific, penta- and hexavalent Ig-M antibodies
WO2019169314A1 (en) * 2018-03-01 2019-09-06 Igm Biosciences, Inc. IgM Fc AND J-CHAIN MUTATIONS THAT AFFECT IgM SERUM HALF-LIFE
US10570191B2 (en) 2015-04-17 2020-02-25 Igm Biosciences, Inc. Multi-valent human immunodeficiency virus antigen binding molecules and uses thereof
US10604559B2 (en) 2015-03-25 2020-03-31 Igm Biosciences, Inc. Multi-valent hepatitis B virus antigen binding molecules and uses thereof
US10787520B2 (en) 2015-03-04 2020-09-29 Igm Biosciences, Inc. Multimeric bispecific binding molecules specific for CD20 and CD3
US10822399B2 (en) 2014-02-10 2020-11-03 Igm Biosciences, Inc. IgA multi-specific binding molecules
WO2021030688A1 (en) 2019-08-15 2021-02-18 Igm Biosciences, Inc. Immunostimulatory multimeric binding molecules
US10975147B2 (en) 2014-04-03 2021-04-13 Igm Biosciences, Inc. Modified J-chain
US11401337B2 (en) 2017-04-07 2022-08-02 Igm Biosciences, Inc. Modified human IgM constant regions for modulation of complement-dependent cytolysis effector function
JP2022545655A (ja) * 2019-08-17 2022-10-28 アイジーエム バイオサイエンシズ インコーポレイテッド 多量体の二重特異性抗ｃｄ１２３結合分子及びその使用
WO2022256740A1 (en) 2021-06-04 2022-12-08 Curia Ip Holdings, Llc Polymeric fusion proteins and compositions for inducing an immune response against infection
US11542342B2 (en) 2015-09-30 2023-01-03 Igm Biosciences, Inc. Binding molecules with modified J-chain
US11639389B2 (en) 2015-09-30 2023-05-02 Igm Biosciences, Inc. Binding molecules with modified J-chain
EP4087608A4 (en) * 2020-01-06 2024-02-14 IGM Biosciences, Inc. HIGHLY SIALYLATED MULTIMER BINDING MOLECULES

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112022003282A2 (pt) * 2019-08-23 2022-05-24 Igm Biosciences Inc Glicovariantes de igm
US20230212293A1 (en) 2020-04-22 2023-07-06 Igm Biosciences, Inc. Pd-1 agonist multimeric binding molecules
EP4328243A4 (en) * 2021-04-20 2025-05-21 Korea University Research and Business Foundation Asymmetric antibody with improved cytotoxicity against cancer cell
WO2023012147A1 (en) * 2021-08-03 2023-02-09 F. Hoffmann-La Roche Ag Bispecific antibodies and methods of use

Citations (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989001975A1 (en) 1987-08-24 1989-03-09 Celltech Limited Recombinant antibodies and methods for their production
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
WO1998030591A1 (en) * 1997-01-10 1998-07-16 Epicyte Pharmaceutical Inc. Novel epithelial tissue imaging agent
US5831034A (en) 1987-11-13 1998-11-03 Hermann Katinger Human monoclonal anti-HIV-I-antibodies
US5911989A (en) 1995-04-19 1999-06-15 Polynum Scientific Immunbiologische Forschung Gmbh HIV-vaccines
US6676924B2 (en) 1994-10-05 2004-01-13 Immunomedics, Inc. CDR-grafted type III anti-CEA humanized mouse monoclonal antibodies
US20050287153A1 (en) 2002-06-28 2005-12-29 Genentech, Inc. Serum albumin binding peptides for tumor targeting
US20060063234A1 (en) 2003-05-23 2006-03-23 Crucell Holland B.V. Efficient production of IgM in recombinant mammalian cells
US7074403B1 (en) 1999-06-09 2006-07-11 Immunomedics, Inc. Immunotherapy of autoimmune disorders using antibodies which target B-cells
US7109304B2 (en) 2003-07-31 2006-09-19 Immunomedics, Inc. Humanized anti-CD19 antibodies
US7138496B2 (en) 2002-02-08 2006-11-21 Genetastix Corporation Human monoclonal antibodies against human CXCR4
US7238785B2 (en) 2002-03-01 2007-07-03 Immunomedics, Inc. RS7 antibodies
US7251164B2 (en) 2004-11-10 2007-07-31 Innovative Silicon S.A. Circuitry for and method of improving statistical distribution of integrated circuits
US7282567B2 (en) 2002-06-14 2007-10-16 Immunomedics, Inc. Monoclonal antibody hPAM4
US7300655B2 (en) 2002-08-01 2007-11-27 Immunomedics, Inc. Alpha-fetoprotein Immu31 antibodies and fusion proteins and methods of use thereof
US7312318B2 (en) 2002-03-01 2007-12-25 Immunomedics, Inc. Internalizing anti-CD74 antibodies and methods of use
US7387773B2 (en) 2001-08-07 2008-06-17 Massey University Vaccine
US20080145420A1 (en) * 2006-12-13 2008-06-19 Simon Michael R HUMAN SECRETORY IgA FOR THE TREATMENT OF CLOSTRIDIUM DIFFICILE ASSOCIATED DISEASES
US7541440B2 (en) 2002-09-30 2009-06-02 Immunomedics, Inc. Chimeric, human and humanized anti-granulocyte antibodies and methods of use
WO2009130575A2 (en) 2008-04-22 2009-10-29 Universita' Degli Studi Di Verona Isolated monoclonal antibody or fragment thereof binding prostate specific membrane antigen, conjugates and uses thereof
US7612180B2 (en) 2005-03-03 2009-11-03 Immunomedics, Inc. Humanized L243 antibodies
US8333971B2 (en) 2006-05-15 2012-12-18 Immunomedics, Inc. Methods and compositions for treatment of human immunodeficiency virus infection with conjugated antibodies or antibody fragments
WO2015153912A1 (en) * 2014-04-03 2015-10-08 Igm Biosciences, Inc. Modified j-chain

Family Cites Families (134)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
EP0642585B1 (en) 1992-05-18 2005-12-28 Genentech, Inc. Activation of oligomerizing receptors by using fused receptor ligands
US6476198B1 (en) 1993-07-13 2002-11-05 The Scripps Research Institute Multispecific and multivalent antigen-binding polypeptide molecules
UA40577C2 (uk) 1993-08-02 2001-08-15 Мерк Патент Гмбх Біспецифічна молекула, що використовується для лізису пухлинних клітин, спосіб її одержання, моноклональне антитіло (варіанти), фармацевтичний препарат, фармацевтичний набір (варіанти), спосіб видалення пухлинних клітин
AU697387C (en) 1994-09-16 2006-03-02 Austin Research Institute Cancer and Anti-inflammatory Syndicate No 1 Polypeptides with Fc binding ability
IL111196A0 (en) 1994-10-07 1994-12-29 Yeda Res & Dev Peptides and pharmaceutical compositions comprising them
US6808709B1 (en) 1994-12-30 2004-10-26 The Regents Of The University Of California Immunoglobulins containing protection proteins and their use
US6165463A (en) 1997-10-16 2000-12-26 Inhale Therapeutic Systems, Inc. Dispersible antibody compositions and methods for their preparation and use
US20050003431A1 (en) 1996-08-16 2005-01-06 Wucherpfennig Kai W. Monovalent, multivalent, and multimeric MHC binding domain fusion proteins and conjugates, and uses therefor
US8212004B2 (en) 1999-03-02 2012-07-03 Human Genome Sciences, Inc. Neutrokine-alpha fusion proteins
EP1015493A1 (en) 1997-01-10 2000-07-05 EPIcyte Pharmaceutical, Inc. Novel epithelial tissue targeting agent
US20040009166A1 (en) 1997-04-30 2004-01-15 Filpula David R. Single chain antigen-binding polypeptides for polymer conjugation
WO1999054484A1 (en) 1998-04-20 1999-10-28 The Regents Of The University Of California Modified immunoglobulin molecules and methods for use thereof
SK288176B6 (sk) 1999-01-07 2014-04-02 Zymogenetics, Inc. Farmaceutický prostriedok obsahujúci fúzny proteín, izolovaná molekula polynukleotidu, expresný vektor, kultivovaná bunka, spôsob prípravy polypeptidu a izolovaný polypeptid
WO2000061637A1 (en) 1999-04-14 2000-10-19 Smithkline Beecham Corporation Erythropoietin receptor antibodies
AU6781700A (en) 1999-08-17 2001-03-13 Health Research Institute Genetic system and self-cleaving inteins derived therefrom, bioseparations and protein purification employing same, and methods for determining critical, generalizable amino acid residues for varying intein activity
NZ517202A (en) 1999-08-24 2004-05-28 Medarex Inc Human CTLA-4 antibodies and their uses
ES2637801T3 (es) 2000-04-11 2017-10-17 Genentech, Inc. Anticuerpos multivalentes y usos de los mismos
US20020168367A1 (en) 2000-04-28 2002-11-14 Planet Biotechnology Incorporated Novel immunoadhesins for treating and preventing viral and bacterial diseases
US7951378B2 (en) 2000-04-28 2011-05-31 Planet Biotechnology Inc. Immunoadhesin comprising a chimeric ICAM-1 molecule produced in a plant
US7947275B2 (en) 2000-05-10 2011-05-24 Signe Biopharma, Inc. Compositions and methods for demonstrating secretory immune system regulation of steroid hormone responsive cancer cell growth
AU2001277531A1 (en) 2000-07-10 2002-01-21 Novartis Ag Bifunctional molecules and vectors complexed therewith for targeted gene delivery
WO2005056601A2 (en) 2003-12-05 2005-06-23 Schreiber John R Human anti-pseudomonas-aeruginosa antibodies derived from transgenic xenomouse?
JP2004514423A (ja) 2000-09-07 2004-05-20 シュライバー，　ジョン　アール． トランスジェニックｘｅｎｏｍｏｕｓｅ（登録商標）から獲得されるｐｅｕｄｏｍｏｎａｓａｅｒｕｇｉｎｏｓａｌｐｓに対するヒト抗体
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US7829084B2 (en) 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
KR100900176B1 (ko) 2001-03-07 2009-06-02 메르크 파텐트 게엠베하 하이브리드 이소타입 항체 부분구조를 포함하는 단백질을위한 발현 기술
US7402312B2 (en) * 2001-04-13 2008-07-22 Human Genome Sciences, Inc. Antibodies to vascular endothelial growth factor 2 (VEGF-2)
US20050129616A1 (en) 2001-05-25 2005-06-16 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to TRAIL receptors
ES2559002T3 (es) 2001-10-23 2016-02-10 Psma Development Company, L.L.C. Anticuerpos contra PSMA
CA2476166C (en) 2002-02-14 2011-11-15 Immunomedics, Inc. Anti-cd20 antibodies and fusion proteins thereof and methods of use
IL164287A0 (en) 2002-04-12 2005-12-18 Medarex Inc Methods of treatment using ctla-4 antibodies
US7601351B1 (en) * 2002-06-26 2009-10-13 Human Genome Sciences, Inc. Antibodies against protective antigen
PT2314629E (pt) 2002-07-18 2014-01-22 Merus B V Produção recombinante de misturas de anticorpos
WO2004028339A2 (en) 2002-09-27 2004-04-08 Brigham And Women's Hospital, Inc. Treatment of patients with multiple sclerosis based on gene expression changes in central nervous system tissues
US20050014932A1 (en) 2003-05-15 2005-01-20 Iogenetics, Llc Targeted biocides
AR044388A1 (es) 2003-05-20 2005-09-07 Applied Molecular Evolution Moleculas de union a cd20
TW200510532A (en) 2003-07-15 2005-03-16 Chugai Pharmaceutical Co Ltd IgM production by transformed cell and method of quantifying the same
US8147832B2 (en) 2003-08-14 2012-04-03 Merck Patent Gmbh CD20-binding polypeptide compositions and methods
US7803914B2 (en) 2003-10-09 2010-09-28 Chugai Seiyaku Kabushiki Kaisha Methods for stabilizing protein solutions
JP4948174B2 (ja) 2003-10-16 2012-06-06 マイクロメット アクツィエン ゲゼルシャフト 多重特異的脱免疫ｃｄ３−結合物質
FR2861255B1 (fr) 2003-10-24 2006-02-17 Centre Nat Rech Scient Mammifere non-humain transgenique pour la region constante de la chaine lourde des immunoglobulines humaines de classe a et ses applications.
WO2005077981A2 (en) 2003-12-22 2005-08-25 Xencor, Inc. Fc POLYPEPTIDES WITH NOVEL Fc LIGAND BINDING SITES
US7850962B2 (en) 2004-04-20 2010-12-14 Genmab A/S Human monoclonal antibodies against CD20
WO2006052641A2 (en) 2004-11-05 2006-05-18 Palingen, Inc. Antibody induced cell membrane wounding
WO2006063067A2 (en) 2004-12-09 2006-06-15 La Jolla Institute For Allergy And Immunology Novel tnf receptor regulatory domain
US8349332B2 (en) 2005-04-06 2013-01-08 Ibc Pharmaceuticals, Inc. Multiple signaling pathways induced by hexavalent, monospecific and bispecific antibodies for enhanced toxicity to B-cell lymphomas and other diseases
US20070014720A1 (en) 2005-06-02 2007-01-18 Gadi Gazit-Bornstein Antibodies directed to CD20 and uses thereof
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
TW200732350A (en) 2005-10-21 2007-09-01 Amgen Inc Methods for generating monovalent IgG
RU2008129827A (ru) 2005-12-21 2010-01-27 МЕДИММЬЮН, ЭлЭлСи (US) МОЛЕКУЛЫ EphA2-BiTE И ИХ ПРИМЕНЕНИЕ
EP2021500B1 (en) 2006-05-19 2014-12-31 Children, Youth and Women's Health Service Selective modulation of receptor signalling
EP2418223A3 (en) 2006-06-12 2013-01-16 Emergent Product Development Seattle, LLC Single-chain multivalent binding proteins with effector function
EP2066337A2 (en) * 2006-08-04 2009-06-10 Amylin Pharmaceuticals, Inc. Use of exendins, exendin agonists and glp-1 receptor agonists for altering the concentration of fibrinogen
KR101544108B1 (ko) 2006-09-08 2015-08-13 애브비 바하마스 리미티드 인터루킨-13 결합 단백질
US9382327B2 (en) 2006-10-10 2016-07-05 Vaccinex, Inc. Anti-CD20 antibodies and methods of use
NZ576445A (en) 2006-11-02 2012-03-30 Daniel J Capon Hybrid immunoglobulins with moving parts
EP2087111A2 (en) * 2007-03-19 2009-08-12 Medimmune Limited Polypeptide variants
US20100298223A1 (en) 2007-05-02 2010-11-25 Dietmar Rudolf Fries Fibrinogen for treatment of bleeding in trauma and platelet disorders
WO2009013620A2 (en) 2007-06-11 2009-01-29 Erasmus University Medical Center Rotterdam Homologous recombination
EP2195342A1 (en) 2007-09-07 2010-06-16 Ablynx N.V. Binding molecules with multiple binding sites, compositions comprising the same and uses thereof
US8877688B2 (en) 2007-09-14 2014-11-04 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
EP2219458B1 (en) 2007-11-08 2015-07-15 Cytimmune Sciences, Inc. Compositions and methods for generating antibodies
EP2254592B1 (en) 2008-02-28 2019-06-05 Dako Denmark A/S Mhc multimers in borrelia diagnostics and disease
CN102149727A (zh) 2008-07-11 2011-08-10 航道生物技术有限责任公司 包含抗体替代卡帕轻链序列的构建体和文库
US10369204B2 (en) 2008-10-02 2019-08-06 Dako Denmark A/S Molecular vaccines for infectious disease
DK2356270T3 (da) 2008-11-07 2016-12-12 Fabrus Llc Kombinatoriske antistofbiblioteker og anvendelser deraf
JP5739865B2 (ja) * 2009-03-24 2015-06-24 バイエル・ヘルスケア・エルエルシー 第ｖｉｉｉ因子変異体および使用の方法
EP2509997B1 (en) 2009-12-07 2017-08-30 i2 Pharmaceuticals, Inc. Conjugates comprising an antibody surrogate scaffold with improved pharmacokinetic properties
SG181952A1 (en) 2009-12-29 2012-07-30 Emergent Product Dev Seattle Heterodimer binding proteins and uses thereof
WO2011100403A1 (en) 2010-02-10 2011-08-18 Immunogen, Inc Cd20 antibodies and uses thereof
US9085623B2 (en) 2010-02-11 2015-07-21 Alexion Pharmaceuticals, Inc. Therapeutic methods using anti-CD200 antibodies
WO2012054077A2 (en) 2010-10-19 2012-04-26 Mayo Foundation For Medical Education And Research Human antibodies and diagnostic and therapeutic uses thereof for the treatment of neurological disease
US20120195900A1 (en) 2010-12-22 2012-08-02 Abbott Laboratories Tri-variable domain binding proteins and uses thereof
MX2014004980A (es) 2011-10-24 2014-09-11 Abbvie Inc Inmunoaglutinantes biespecificos dirigidos contra tnf e il-17.
US9253965B2 (en) 2012-03-28 2016-02-09 Kymab Limited Animal models and therapeutic molecules
GB201122047D0 (en) 2011-12-21 2012-02-01 Kymab Ltd Transgenic animals
US20140359902A1 (en) 2011-12-16 2014-12-04 Synthon Biopharmaceuticals B.V. EXPRESSION OF SECRETORY IgA ANTIBODIES IN DUCKWEED
CA2863714C (en) 2012-02-08 2022-07-05 Igm Biosciences, Inc. Cdim binding proteins and uses thereof
AU2013244916B2 (en) 2012-04-05 2017-08-03 Gottfried Himmler Secretory immunoglobulin complex
ES2655077T3 (es) 2012-04-17 2018-02-16 Mayo Foundation For Medical Education And Research Anticuerpos humanos y secuencias de unión específicos del mismo para uso en accidente cerebrovascular e isquemia y condiciones isquémicas
KR102177252B1 (ko) 2012-04-23 2020-11-10 가부시키가이샤 에스 앤드 케이 바이오파마 락토페린 융합 단백질 및 그의 제조방법
US20150175678A1 (en) 2012-06-15 2015-06-25 Beth Israel Deaconess Medical Center, Inc. IgA CD4i ANTIBODIES AND METHODS OF TREATMENT USING SAME
WO2014022592A1 (en) 2012-08-02 2014-02-06 Jn Biosciences Llc Antibodies or fusion proteins multimerized via cysteine mutation and a mu tailpiece
JOP20200236A1 (ar) 2012-09-21 2017-06-16 Regeneron Pharma الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
WO2014124457A1 (en) 2013-02-11 2014-08-14 University Of Louisville Research Foundation, Inc. Methods for producing antibodies
US9487773B2 (en) 2013-03-01 2016-11-08 Technophage, Investigacao E Desenvolvimento Em Biotecnologia, Sa Cell-based methods for coupling protein interactions and binding molecule selection
EP2968587A2 (en) * 2013-03-13 2016-01-20 Bristol-Myers Squibb Company Fibronectin based scaffold domains linked to serum albumin or a moiety binding thereto
GB201311487D0 (en) 2013-06-27 2013-08-14 Alligator Bioscience Ab Bispecific molecules
US20150038682A1 (en) 2013-08-02 2015-02-05 Jn Biosciences Llc Antibodies or fusion proteins multimerized via homomultimerizing peptide
CA2922830A1 (en) 2013-09-05 2015-04-16 Igm Biosciences, Inc. Constant chain modified bispecific, penta- and hexavalent ig-m antibodies
WO2015037000A1 (en) 2013-09-11 2015-03-19 Compugen Ltd Vstm5 polypeptides and uses thereof as a drug for treatment of cancer, infectious diseases and immune related diseases
NZ720353A (en) 2013-12-30 2019-12-20 Epimab Biotherapeutics Inc Fabs-in-tandem immunoglobulin and uses thereof
CA2936877C (en) 2014-01-16 2023-03-28 Mario Umberto Francesco MONDELLI Neutralizing human monoclonal antibodies against hepatitis b virus surface antigen
AU2015213593B2 (en) 2014-02-10 2020-09-03 Igm Biosciences, Inc. IgA multi-specific binding molecules
TWI777174B (zh) 2014-03-14 2022-09-11 瑞士商諾華公司 針對lag-3之抗體分子及其用途
EP3750918A1 (en) 2015-01-20 2020-12-16 IGM Biosciences, Inc. Tumor necrosis factor (tnf) superfamily receptor binding molecules and uses thereof
CN115093479A (zh) 2015-03-04 2022-09-23 Igm生物科学股份有限公司 Cd20结合分子及其用途
JP6882184B2 (ja) 2015-03-25 2021-06-02 アイジーエム バイオサイエンシズ インコーポレイテッド 多価ｂ型肝炎ウイルス抗原結合分子およびその使用
WO2016168758A1 (en) 2015-04-17 2016-10-20 Igm Biosciences, Inc. Multi-valent human immunodeficiency virus antigen binding molecules and uses thereof
NZ739830A (en) 2015-07-12 2021-12-24 Hangzhou Dac Biotech Co Ltd Bridge linkers for conjugation of cell-binding molecules
US11639389B2 (en) 2015-09-30 2023-05-02 Igm Biosciences, Inc. Binding molecules with modified J-chain
DK3355913T3 (da) 2015-09-30 2024-12-02 Igm Biosciences Inc Bindingsmolekyler med modificeret j-kæde
PL3455257T3 (pl) 2016-05-09 2022-01-17 Igm Biosciences Inc. Przeciwciała anty-pd-l1
US20190330374A1 (en) 2016-07-20 2019-10-31 Igm Biosciences, Inc. Multimeric ox40 binding molecules and uses thereof
US20190330360A1 (en) 2016-07-20 2019-10-31 Igm Biosciences, Inc. Multimeric gitr binding molecules and uses thereof
US20190338040A1 (en) 2016-07-20 2019-11-07 Igm Biosciences, Inc. Multimeric cd137/4-1bb binding molecules and uses thereof
EP3496536A4 (en) 2016-07-20 2020-02-12 IGM Biosciences, Inc. MULTIMERE CD40-BINDING MOLECULES AND USES THEREOF
US11401337B2 (en) 2017-04-07 2022-08-02 Igm Biosciences, Inc. Modified human IgM constant regions for modulation of complement-dependent cytolysis effector function
US20200392239A1 (en) 2018-02-26 2020-12-17 Igm Biosciences, Inc. Use of a multimeric anti-dr5 binding molecule in combination with a chemotherapeutic agent for treating cancer
WO2019169314A1 (en) 2018-03-01 2019-09-06 Igm Biosciences, Inc. IgM Fc AND J-CHAIN MUTATIONS THAT AFFECT IgM SERUM HALF-LIFE
KR20210083260A (ko) 2018-10-23 2021-07-06 아이쥐엠 바이오사이언스 인코포레이티드 다가 IgM- 및 IgA-Fc 기반 결합 분자
US20220106398A1 (en) 2019-02-08 2022-04-07 Igm Biosciences, Inc. Anti-gitr antigen-binding domains and uses thereof
CN114269785A (zh) 2019-08-15 2022-04-01 Igm生物科学股份有限公司 免疫刺激性多聚体结合分子
KR20220045030A (ko) 2019-08-17 2022-04-12 아이쥐엠 바이오사이언스 인코포레이티드 다량체성 이중특이적 항-cd123 결합 분자 및 이의 용도
BR112022003282A2 (pt) 2019-08-23 2022-05-24 Igm Biosciences Inc Glicovariantes de igm
AU2020351205A1 (en) 2019-09-19 2022-04-14 Igm Biosciences, Inc. Multimeric antibodies with enhanced selectivity for cells with high target density
BR112022013071A2 (pt) 2020-01-06 2022-09-20 Igm Biosciences Inc Moléculas de ligação multiméricas altamente sialiladas
US20230212293A1 (en) 2020-04-22 2023-07-06 Igm Biosciences, Inc. Pd-1 agonist multimeric binding molecules
MX2022014259A (es) 2020-05-12 2022-12-07 Igm Biosciences Inc Uso de una molecula de union anti-dr5 multimerica en combinacion con una terapia contra el cancer para tratar el cancer.
CA3187008A1 (en) 2020-07-27 2022-02-03 Paul R. Hinton Multimeric coronavirus binding molecules and uses thereof
US20240002526A1 (en) 2020-11-17 2024-01-04 Igm Biosciences, Inc. Uses of effector cell engaging molecules with moieties of differing potencies
MX2023009615A (es) 2021-02-17 2023-08-24 Igm Biosciences Inc Moleculas de union anti-cd123 y usos de estas.
WO2022177870A1 (en) 2021-02-17 2022-08-25 The Board Of Regents Of The University Of Texas System Multimeric sars-cov-2 binding molecules and uses thereof
WO2023064766A1 (en) 2021-10-11 2023-04-20 Igm Biosciences, Inc. Lateral flow device and uses thereof
WO2023064900A1 (en) 2021-10-15 2023-04-20 Igm Biosciences, Inc. Methods of use of multimeric anti-pd-l1 binding molecules
JP2025506341A (ja) 2022-02-03 2025-03-11 アイジーエム バイオサイエンシズ インコーポレイテッド 抗ｃｄ３８結合分子及びその使用
WO2023178253A2 (en) 2022-03-18 2023-09-21 Igm Biosciences, Inc. Use of a multimeric anti-pd-l1 binding molecule in combination with a monoclonal antibody therapy
WO2024073700A2 (en) 2022-09-30 2024-04-04 Igm Biosciences, Inc. Methods of treating autoimmune disorders using multimeric anti-cd20/anti-cd3 antibodies
WO2024138072A1 (en) 2022-12-22 2024-06-27 Igm Biosciences, Inc. Methods of treating autoimmune disorders using multimeric anti-cd38/anti-cd3 antibodies
JP2026502759A (ja) 2023-01-06 2026-01-27 アイジーエム バイオサイエンシズ インコーポレイテッド Ｔ細胞共刺激多量体結合分子及びその使用
WO2024148339A1 (en) 2023-01-06 2024-07-11 Igm Biosciences, Inc. Use of a multimeric anti-dr5 antibody for treating cancer
WO2024229151A2 (en) 2023-05-02 2024-11-07 Igm Biosciences, Inc. Multimeric coronavirus binding molecules and uses thereof

Patent Citations (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
WO1989001975A1 (en) 1987-08-24 1989-03-09 Celltech Limited Recombinant antibodies and methods for their production
US5831034A (en) 1987-11-13 1998-11-03 Hermann Katinger Human monoclonal anti-HIV-I-antibodies
US6676924B2 (en) 1994-10-05 2004-01-13 Immunomedics, Inc. CDR-grafted type III anti-CEA humanized mouse monoclonal antibodies
US5911989A (en) 1995-04-19 1999-06-15 Polynum Scientific Immunbiologische Forschung Gmbh HIV-vaccines
WO1998030591A1 (en) * 1997-01-10 1998-07-16 Epicyte Pharmaceutical Inc. Novel epithelial tissue imaging agent
US7074403B1 (en) 1999-06-09 2006-07-11 Immunomedics, Inc. Immunotherapy of autoimmune disorders using antibodies which target B-cells
US7387773B2 (en) 2001-08-07 2008-06-17 Massey University Vaccine
US7138496B2 (en) 2002-02-08 2006-11-21 Genetastix Corporation Human monoclonal antibodies against human CXCR4
US7238785B2 (en) 2002-03-01 2007-07-03 Immunomedics, Inc. RS7 antibodies
US7312318B2 (en) 2002-03-01 2007-12-25 Immunomedics, Inc. Internalizing anti-CD74 antibodies and methods of use
US7282567B2 (en) 2002-06-14 2007-10-16 Immunomedics, Inc. Monoclonal antibody hPAM4
US20050287153A1 (en) 2002-06-28 2005-12-29 Genentech, Inc. Serum albumin binding peptides for tumor targeting
US7300655B2 (en) 2002-08-01 2007-11-27 Immunomedics, Inc. Alpha-fetoprotein Immu31 antibodies and fusion proteins and methods of use thereof
US7541440B2 (en) 2002-09-30 2009-06-02 Immunomedics, Inc. Chimeric, human and humanized anti-granulocyte antibodies and methods of use
US20060063234A1 (en) 2003-05-23 2006-03-23 Crucell Holland B.V. Efficient production of IgM in recombinant mammalian cells
US7109304B2 (en) 2003-07-31 2006-09-19 Immunomedics, Inc. Humanized anti-CD19 antibodies
US7251164B2 (en) 2004-11-10 2007-07-31 Innovative Silicon S.A. Circuitry for and method of improving statistical distribution of integrated circuits
US7612180B2 (en) 2005-03-03 2009-11-03 Immunomedics, Inc. Humanized L243 antibodies
US8333971B2 (en) 2006-05-15 2012-12-18 Immunomedics, Inc. Methods and compositions for treatment of human immunodeficiency virus infection with conjugated antibodies or antibody fragments
US20080145420A1 (en) * 2006-12-13 2008-06-19 Simon Michael R HUMAN SECRETORY IgA FOR THE TREATMENT OF CLOSTRIDIUM DIFFICILE ASSOCIATED DISEASES
WO2009130575A2 (en) 2008-04-22 2009-10-29 Universita' Degli Studi Di Verona Isolated monoclonal antibody or fragment thereof binding prostate specific membrane antigen, conjugates and uses thereof
WO2015153912A1 (en) * 2014-04-03 2015-10-08 Igm Biosciences, Inc. Modified j-chain

Non-Patent Citations (63)

* Cited by examiner, † Cited by third party
Title
"Current Protocols in Protein Science", 15 May 2001, JOHN WILEY & SONS, INC., US, ISSN: 1934-3655, article JOHANNES U. AMMANN ET AL: "Development and Use of IgM/J-Chain Fusion Proteins for Characterization of Immunoglobulin Superfamily Ligand-Receptor Interactions", pages: 19.24.1 - 19.24.11, XP055333814, DOI: 10.1002/0471140864.ps1924s75 *
AGGARWAL ET AL., BLOOD, vol. 119, 2012, pages 651 - 665
ANDERSEN ET AL., JBC, vol. 289, no. 19, 2014, pages 13492 - 13502
AZUMA ET AL., CLIN CANCER RES, vol. 13, no. 9, 2007, pages 2745 - 2750
BIOTECHNOLOGY AND BIOENGINEERING, vol. 87, pages 553 - 545
CHINTALACHARUVU ET AL., CLIN IMMUNOL, vol. 101, no. 1, 2001, pages 21 - 31
CHINTALACHARUVU K R ET AL: "Hybrid IgA2/IgG1 antibodies with tailor-made effector functions", CLINICAL IMMUNOLOGY, ACADEMIC PRESS, US, vol. 101, no. 1, 1 October 2001 (2001-10-01), pages 21 - 31, XP002999715, ISSN: 1521-6616, DOI: 10.1006/CLIM.2001.5083 *
CLACKSON ET AL., NATURE, vol. 352, 1991, pages 624 - 628
CZAJKOWSKY; SHAO, PNAS, vol. 106, no. 35, 2009, pages 14960 - 14965
DANIEL P. STITES, ABBA I. TERR AND TRISTRAM G. PARSLOW: "Basic and Clinical Immunology, 8th ed", 1994, APPLETON & LANGE, article "chapter 6", pages: 71
DAVIS ET AL., EUR. J. IMMUNOL., vol. 18, 1988, pages 1001 - 1008
DENNIS ET AL., J. BIOL. CHEM., vol. 277, 2002, pages 35035 - 350,43
DENNIS ET AL., NEUROPSYCHOPHARMACOLOGY REVIEWS, vol. 37, 2012, pages 302 - 303
DENNIS; MARK S. ET AL., J. BIOL. CHEM., vol. 277, 2002, pages 35035 - 35043
DUCRY L; STUMP B, BIOCONJUGATE CHEM., vol. 21, 2010, pages 5 - 13
ELLMAN ET AL., METH. ENZYM., vol. 202, 1991, pages 301 - 336
EL-RASHDYM REDWANA ET AL: "RecombinanthumanJ-chain:Fixtheprotein aggregationsandyieldmaximize", 1 January 2006 (2006-01-01), pages 1595 - 102, XP055333807, Retrieved from the Internet <URL:https://www.researchgate.net/profile/Elrashdy_Redwan/publication/282979117_Recombinant_human_J-chain_Fix_the_protein_aggregations_and_yield_maximize/links/57c9c8b708ae89cd1e81ece3.pdf> *
FRUTIGER ET AL., BIOCHEMISTRY, vol. 31, 1992, pages 12643 - 12647
GARCIA-PARDO ET AL., J. BIOL. CHEM., vol. 256, 1981, pages 11734 - 11738
HOPP ET AL., PEDS, vol. 23, 2010, pages 827 - 833
HOUGHTON ET AL., PNAS, pages 15850 - 15855
JANTINE E. BAKEMA ET AL: "Immunoglobulin A", MABS, vol. 3, no. 4, 1 July 2011 (2011-07-01), pages 352 - 361, XP055185206, ISSN: 1942-0862, DOI: 10.4161/mabs.3.4.16092 *
J-CHAIN, GENE, vol. 108, 1991, pages 193 - 200
JONES ET AL., NATURE, vol. 321, 1986, pages 522 - 525
JONES, A.R.; E.V. SHUSTA: "Blood-brain barrier transport of therapeutics via receptor-mediation", PHARM. RES., vol. 24, 2007, pages 1759 - 1771
JOOS ET AL., ANTIMICROB. AGENTS CHEMOTHER., vol. 50, no. 5, 2006, pages 1773 - 9
JOY YU ZUCHERO ET AL., NEURON, vol. 89, 2016, pages 70 - 82
KLEIN ET AL., PROTEIN ENGINEERING, DESIGN & SELECTION, vol. 27, no. 10, 2014, pages 325 - 330
KLINE ET AL., PHARM RES, 16 December 2014 (2014-12-16)
KOHLER ET AL., NATURE, vol. 256, 1975, pages 495
KOTESWARA ET AL., CLINICAL IMMUNOLOGY, vol. 101, no. 1, 2001, pages 21 - 31
KSIEZAK-REDING ET AL., J BIOL CHEM, vol. 263, 1987, pages 7943 - 47
M. J. MCPHERSON: "Mutagenesis: a Practical Approach", 1991, IRL PRESS
MARKS ET AL., J. MOL. BIOL., vol. 222, 1991, pages 581 - 597
MORDENTI, J. ET AL., TOXICOLOGICAL SCIENCES, vol. 27, no. 5, 1999, pages 536 - 544
MORDENTI, J. ET AL., TOXICOLOGICAL SCIENCES, vol. 52, 1999, pages 101 - 106
MORRISON ET AL., PROC. NATL. ACAD. SCI. USA, vol. 81, 1984, pages 6851 - 6855
MULLER ET AL., MABS, vol. 4, no. 6, 2012, pages 673 - 685
NOCENTINI, G. ET AL., PROC NATL ACAD SCI USA., vol. 94, no. 12, 10 June 1997 (1997-06-10), pages 6216 - 21
NOREN ET AL., SCIENCE, vol. 244, 1989, pages 182
OFEI ET AL., DIABETES, vol. 45, 2011, pages 881 - 85
PARDOLL; DREW M.: "The blockade of immune checkpoints in cancer immunotherapy", NATURE REVIEWS CANCER, vol. 12.4, 2012, pages 252 - 264
PAULIK ET AL., BIOCHEM PHARMACOL, vol. 58, 1999, pages 1781 - 90
PONDERS; RICHARDS, J. MOL. BIOL., vol. 193, 1987, pages 775 - 791
POSTOW; MICHAEL A ET AL.: "Immune Checkpoint Blockade in Cancer Therapy", J CLIN ONCOL., vol. 33, no. 17, 10 June 2015 (2015-06-10), pages 1974 - 82
PRESTA, CURRO OP. STRUCT. BIOL., vol. 2, 1992, pages 593 - 596
REDWAN ET AL., HUMAN ANTIBODIES, vol. 15, 2006, pages 95 - 102
RIECHMANN ET AL., NATURE, vol. 332, 1988, pages 323 - 329
ROOPENIAN D.C. ET AL., NATURE REVIEWS IMMUNOLOGY, vol. 7, 2007, pages 715 - 725
SASKIA MEYER ET AL: "Improved in vivo anti-tumor effects of IgA-Her2 antibodies through half-life extension and serum exposure enhancement by FcRn targeting", MABS, vol. 8, no. 1, 14 October 2015 (2015-10-14), US, pages 87 - 98, XP055335017, ISSN: 1942-0862, DOI: 10.1080/19420862.2015.1106658 *
SINGLETON ET AL.: "Dictionary of Microbiology and Molecular Biology 2nd ed.", 1994, J. WILEY & SONS
SMITH ET AL., J IMMUNOL, vol. 154, 1995, pages 2226 - 2236
SORENSEN ET AL., INT. IMMUNOL., vol. 12, no. 1, 2000, pages 19 - 27
STROP ET AL., BIOCONJUGATE CHEMISTRY, vol. 26, no. 4, 2015, pages 650 - 9
SYMERSKY ET AL., MOL IMMUNOL, vol. 37, 2000, pages 133 - 140
TABRIZI ET AL., AAPS J., vol. 12, no. 1, March 2010 (2010-03-01), pages 33 - 43
TCHOUDAKOVA A ET AL.: "High level expression of functional human IgMs in human PER.C6 cells", MABS, vol. 1, no. 2, 2009, pages 163 - 171
VASQUEZ ET AL., PLOS ONE, vol. 6, 2011, pages E20594
VCELAR ET AL., AIDS, vol. 21, no. 16, 2007, pages 2161 - 2170
WANG ET AL., NATURE, vol. 84, no. 5, 2008
WOOD ET AL., J. IMMUNOL., vol. 145, 1990, pages 3011 - 3016
YOO ET AL., J. BIOL. CHEM., vol. 274, no. 47, 1999, pages 33771 - 33777
YU ET AL., SCIENCE TRANSLATIONAL MEDICINE, vol. 16, 2014, pages 261

Cited By (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10351631B2 (en) 2013-09-05 2019-07-16 Igm Biosciences, Inc. Constant chain modified bispecific, penta- and hexavalent Ig-M antibodies
US10822399B2 (en) 2014-02-10 2020-11-03 Igm Biosciences, Inc. IgA multi-specific binding molecules
US10975147B2 (en) 2014-04-03 2021-04-13 Igm Biosciences, Inc. Modified J-chain
US11555075B2 (en) 2014-04-03 2023-01-17 Igm Biosciences, Inc. Modified J-chain
US9938347B2 (en) 2015-01-20 2018-04-10 Igm Biosciences A/S Tumor necrosis factor (TNF) superfamily receptor IgM antibodies and uses thereof
US11578131B2 (en) 2015-01-20 2023-02-14 Igm Biosciences, Inc. Polynucleotides encoding death domain-containing receptor-5 (DR5) binding molecules
US10689449B2 (en) 2015-01-20 2020-06-23 Igm Biosciences, Inc. Multimeric death domain-containing receptor-5 (DR5) antibodies and uses thereof
US10787520B2 (en) 2015-03-04 2020-09-29 Igm Biosciences, Inc. Multimeric bispecific binding molecules specific for CD20 and CD3
US10604559B2 (en) 2015-03-25 2020-03-31 Igm Biosciences, Inc. Multi-valent hepatitis B virus antigen binding molecules and uses thereof
US11535664B2 (en) 2015-03-25 2022-12-27 Igm Biosciences, Inc. Multi-valent hepatitis B virus antigen binding molecules and uses thereof
US11192941B2 (en) 2015-04-17 2021-12-07 Igm Biosciences, Inc. Multi-valent human immunodeficiency virus antigen binding molecules and uses thereof
US10570191B2 (en) 2015-04-17 2020-02-25 Igm Biosciences, Inc. Multi-valent human immunodeficiency virus antigen binding molecules and uses thereof
US12486336B2 (en) 2015-09-30 2025-12-02 Igm Biosciences, Inc. Binding molecules with modified J-chain
US11639389B2 (en) 2015-09-30 2023-05-02 Igm Biosciences, Inc. Binding molecules with modified J-chain
US11542342B2 (en) 2015-09-30 2023-01-03 Igm Biosciences, Inc. Binding molecules with modified J-chain
US10954302B2 (en) 2016-05-09 2021-03-23 Igm Biosciences, Inc. Anti-PD-L1 antibodies
WO2017196867A1 (en) * 2016-05-09 2017-11-16 Igm Biosciences, Inc. Anti-pd-l1 antibodies
US11401337B2 (en) 2017-04-07 2022-08-02 Igm Biosciences, Inc. Modified human IgM constant regions for modulation of complement-dependent cytolysis effector function
CN111787951A (zh) * 2018-03-01 2020-10-16 Igm生物科学股份有限公司 影响IgM血清半衰期的IgM Fc和J链突变
KR20200128391A (ko) * 2018-03-01 2020-11-12 아이쥐엠 바이오사이언스 인코포레이티드 IgM 혈청 반감기에 영향을 미치는 IgM Fc 및 J-쇄 돌연변이
CN111787951B (zh) * 2018-03-01 2025-06-17 Igm生物科学股份有限公司 影响IgM血清半衰期的IgM Fc和J链突变
US10899835B2 (en) 2018-03-01 2021-01-26 Igm Biosciences, Inc. IgM Fc and J-chain mutations that affect IgM serum half-life
EP3758752A4 (en) * 2018-03-01 2021-12-15 IGM Biosciences Inc. IGM-FC AND J-CHAIN MUTATIONS AFFECTING IGM SERUM HALF-LIFE
JP2021514618A (ja) * 2018-03-01 2021-06-17 アイジーエム バイオサイエンシズ インコーポレイテッド ＩｇＭ血清半減期に影響を及ぼすＩｇＭ Ｆｃ及びＪ鎖の変異
WO2019169314A1 (en) * 2018-03-01 2019-09-06 Igm Biosciences, Inc. IgM Fc AND J-CHAIN MUTATIONS THAT AFFECT IgM SERUM HALF-LIFE
KR102745232B1 (ko) * 2018-03-01 2024-12-26 아이쥐엠 바이오사이언스 인코포레이티드 IgM 혈청 반감기에 영향을 미치는 IgM Fc 및 J-쇄 돌연변이
JP7376490B2 (ja) 2018-03-01 2023-11-08 アイジーエム バイオサイエンシズ インコーポレイテッド ＩｇＭ血清半減期に影響を及ぼすＩｇＭ Ｆｃ及びＪ鎖の変異
WO2021030688A1 (en) 2019-08-15 2021-02-18 Igm Biosciences, Inc. Immunostimulatory multimeric binding molecules
EP4013796A4 (en) * 2019-08-17 2023-08-02 IGM Biosciences Inc. MULTIMERIC BISPECIFIC ANTI-CD123 BINDING MOLECULES AND THEIR USES
JP7585305B2 (ja) 2019-08-17 2024-11-18 アイジーエム バイオサイエンシズ インコーポレイテッド 多量体の二重特異性抗ｃｄ１２３結合分子及びその使用
JP2022545655A (ja) * 2019-08-17 2022-10-28 アイジーエム バイオサイエンシズ インコーポレイテッド 多量体の二重特異性抗ｃｄ１２３結合分子及びその使用
EP4087608A4 (en) * 2020-01-06 2024-02-14 IGM Biosciences, Inc. HIGHLY SIALYLATED MULTIMER BINDING MOLECULES
WO2022256740A1 (en) 2021-06-04 2022-12-08 Curia Ip Holdings, Llc Polymeric fusion proteins and compositions for inducing an immune response against infection

Also Published As

Publication number Publication date
EP3824903A1 (en) 2021-05-26
AU2016329197A1 (en) 2018-04-12
US11542342B2 (en) 2023-01-03
HUE069387T2 (hu) 2025-03-28
JP7065766B2 (ja) 2022-05-12
SI3355913T1 (sl) 2025-01-31
DK3355913T3 (da) 2024-12-02
CA2999284A1 (en) 2017-04-06
PL3355913T3 (pl) 2025-02-17
EP3355913A1 (en) 2018-08-08
CN108463245A (zh) 2018-08-28
EP3355913B1 (en) 2024-10-30
AU2021200348B2 (en) 2024-07-11
US12486336B2 (en) 2025-12-02
PT3355913T (pt) 2024-12-18
FI3355913T3 (fi) 2024-12-02
US10618978B2 (en) 2020-04-14
HK1252791A1 (zh) 2019-06-06
AU2016329197B2 (en) 2021-01-21
US20230203201A1 (en) 2023-06-29
JP2018535932A (ja) 2018-12-06
CA2999284C (en) 2023-06-13
JP7314356B2 (ja) 2023-07-25
AU2021200348A1 (en) 2021-03-18
JP2022105085A (ja) 2022-07-12
US20180265596A1 (en) 2018-09-20
US20200255546A1 (en) 2020-08-13
ES2996834T3 (en) 2025-02-13

Similar Documents

Publication Publication Date Title
US12486336B2 (en) Binding molecules with modified J-chain
EP3356401B1 (en) Binding molecules with modified j-chain
US20250368737A1 (en) Low ph pharmaceutical composition comprising t cell engaging antibody constructs
JP2020018298A (ja) Ｃｌｄｎ１８．２及びｃｄ３に対する抗体コンストラクト
KR20190141243A (ko) 개선된 저장 및 투여를 위한 이중특이적 항체 구축물을 포함하는 약제학적 조성물
JP2021510521A (ja) Ｐｄ−１に対する単一ドメイン抗体及びその変異体
EA039594B1 (ru) Биспецифические конструкции антител к bcma и cd3, вовлекающие т-клетки
US20230235090A1 (en) Bispecific antibody and use thereof
IL304095A (en) Mesothelin binding molecule and its application
US20250188166A1 (en) Il-18 polypeptides fused to immune cell antigen specific binding polypeptides and uses thereof
HK40052862A (en) Binding molecules with modified j-chain
WO2023219121A1 (ja) 抗ｔａａ－抗ｃｄ３多重特異性抗体
JP2026505164A (ja) 抗ｃｍｅｔ抗体及びその使用方法

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16784320

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2999284

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 15764859

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2018516668

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2016329197

Country of ref document: AU

Date of ref document: 20160930

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2016784320

Country of ref document: EP